A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered the primary therapeutic target, and dendritic cells, critical activators of T cell response. The report that will be appearing in the journal Immunity and has been published online suggests potential ways of improving the efficacy and broadening the application of anti-PD-1 therapies.
from Medical Xpress - latest medical and health news stories https://ift.tt/2QJ4OMO
via IFTTT
No comments:
Post a Comment